[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354282-105":3,"doc-detail-354282-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","extrapolation-of-time-to-event-survival-outcomes-of-histology-independent-therapies-bayesian-hierarchical-model","Extrapolation of Time-to-Event Survival Outcomes of Histology-Independent Therapies - Bayesian Hierarchical Model","","Bayesian hierarchical models are used to extrapolate overall survival for histology-independent therapies by borrowing information across tumor sites while capturing outcome heterogeneity. The study extends prior binary-outcome work to time-to-event extrapolation for pembrolizumab-treated MSI-H/dMMR solid tumors. Models with 1- or 2-parameter distributional assumptions are compared to nonhierarchical site-specific approaches. Hierarchical modeling yields similar extrapolated OS trends in several cancers, higher OS in others, and consistently reduced uncertainty.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/extrapolation-of-time-to-event-survival-outcomes-of-histology-independent-therapies-bayesian-hierarchical-model/354282/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/extrapolation-of-time-to-event-survival-outcomes-of-histology-independent-therapies-bayesian-hierarchical-model/354282.png","ImageObject",300,407,{"name":42,"@type":43},"Mabel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address for histology-independent therapies?","Question",{"text":63,"@type":64},"It addresses how to extrapolate time-to-event survival outcomes while modeling heterogeneity and enabling information sharing across tumor sites for cost-effectiveness analysis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do the Bayesian hierarchical models differ from standard nonhierarchical models?",{"text":68,"@type":64},"The Bayesian hierarchical models assume exchangeability of scale or rate parameters among tumor types and share a common shape parameter in the two-parameter versions, whereas standard models fit separately to each tumor site.",{"name":70,"@type":61,"acceptedAnswer":71},"What are the key findings regarding overall survival and uncertainty?",{"text":72,"@type":64},"Extrapolated overall survival is similar between hierarchical and standard models for several cancers, while some show higher estimates with the Bayesian approach. Across all cases, the Bayesian hierarchical models reduce uncertainty compared with nonhierarchical models.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354282,1790363554,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},7971474920318,"https://ap-avatar.wpscdn.com/avatar/74000ee537e6b0ca360?x-image-process=image/resize,m_fixed,w_180,h_180&k=1788430171632181674",8,"Original Research Article  \nExtrapolation of Time-to-Event Survival Outcomes of Histology-Independent Therapies Using a Bayesian Hierarchical Model  \nJan Mikelson, Richard Birnie, Grant McCarthy, Matthew Madin-Warburton, Ruifeng Xu, Justin Chumbley, Raquel Aguiar-Ib´ ˜anez, Mayur Amonkar, Gianluca Baio, and Kate Young  \nMedical Decision Making 2026, Vol. 46(5) 637–648  \n􀀂 The Author(s) 2026  \nArticle reuse guidelines: [sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/0272989X261434969](DOI: 10.1177/0272989X261434969)[ ](DOI: 10.1177/0272989X261434969)[journals.sagepub.com/home/mdm](journals.sagepub.com/home/mdm)  \nIntroduction. Health technology assessment of histology-independent therapies (HITs) requires statistical methods that can capture heterogeneity in outcomes while allowing borrowing of information between tumor sites to inform cost-effectiveness analysis. In this study, we extend previous work on binary outcomes to the application of Bayesian hierarchical models (BHMs) for extrapolation of overall survival from pembrolizumab-treated patients with microsatellite instability-high/deficient mismatch repair solid tumors. Methods. We considered BHMs based on 1-or 2-parameter distributions for extrapolation of survival outcomes. The scale or rate parameter of each model was assumed exchangeable among tumor types, and the shape parameter was assumed the same for all tumor types in the 2-parameter models. We compared overall survival (OS) and estimated mean survival time for each BHM with the corresponding nonhierarchical model. Results. Extrapolated OS showed similar results between the BHM and standard models for colorectal, endometrial, and gastric cancers. Small intestine and biliary cancers showed higher OS estimates with a BHM than the standard models due to a combination of smaller sample sizes, information sharing in the BHM, and the use of a common shape parameter. Estimated mean survival times were similar between the BHMand equivalent standard model. However, the BHM showed reduced uncertainty in all cases. Conclusions. We have demonstrated that BHMs provide a suitable framework to extrapolate time-to-event outcomes for HITs. The results provide extrapolated curves for OS that vary by tumor site, thus capturing and quantifying the inherent heterogeneity within the patient population. BHMs offer advantages in terms of reduced uncertainty around parameters that are often key drivers in cost-effectiveness analyses, such as estimated OS, through the borrowing of information between tumor sites.  \nHighlights  \n􀀂 Bayesian hierarchical models (BHMs) reduced uncertainty in extrapolation of time-to-event outcomes for histology-independent treatments compared with nonhierarchical models fit to each tumor site.  \n􀀂 Reduced uncertainty around the mean survival time is a key factor of cost-effectiveness analyses of histology-independent treatments.  \n􀀂 BHMs provide a suitable framework for extrapolating histology-independent survival outcomes, effectively integrating prior knowledge and explicitly capturing heterogeneity between different tumor sites.  \nCorresponding Author  \nGrant McCarthy, 126 E Lincoln Avenue, Rahway, NJ 07065 USA;([grant.mccarthy@msd.com](grant.mccarthy@msd.com)) .  \nKeywords  \nBayesian hierarchical model, deficient mismatch repair, histology independent, microsatellite instability, multitumor, pembrolizumab, survival analysis  \nDate received: September 23, 2025; accepted: February 23, 2026  \nIntroduction  \nRecent advances in next-generation sequencing have led to the clinical development and regulatory approval of several new cancer therapies that treat patient populations defined by the presence of a genetic mutation or clinical biomarker, not the tumor site, type, or histology. 1,2 In 2017, the US Food and Drug Administration granted the first approval for a histology-independent therapy (HIT) to pembrolizumab for the treatment of micr","cbCaifsp2UAKynal","https://ap.wps.com/l/cbCaifsp2UAKynal","pdf",2602721,12,"English","# Introduction\n# Methods\n## Model structure and assumptions\n# Results\n# Conclusions","[{\"question\":\"What problem does the study address for histology-independent therapies?\",\"answer\":\"It addresses how to extrapolate time-to-event survival outcomes while modeling heterogeneity and enabling information sharing across tumor sites for cost-effectiveness analysis.\"},{\"question\":\"How do the Bayesian hierarchical models differ from standard nonhierarchical models?\",\"answer\":\"The Bayesian hierarchical models assume exchangeability of scale or rate parameters among tumor types and share a common shape parameter in the two-parameter versions, whereas standard models fit separately to each tumor site.\"},{\"question\":\"What are the key findings regarding overall survival and uncertainty?\",\"answer\":\"Extrapolated overall survival is similar between hierarchical and standard models for several cancers, while some show higher estimates with the Bayesian approach. Across all cases, the Bayesian hierarchical models reduce uncertainty compared with nonhierarchical models.\"}]","Extrapolation of Time-to-Event Survival Outcomes of Histology-Independent Therapies - Bayesian Hierarchical Model | PDF",1790109860,30,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2124555285ec0c8e1f3db834ff85a2ae.webp",983,1296,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81e9df8c32c0379632f7ded7c1f010a0.webp",982,1294,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4adaa5e78d5d13b0ac44447af2fe84f5.webp",981,1293,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dbc2baf39bfab59ae7252dde8bd8521d.webp",980,1292,{"code":4,"msg":82,"data":117},[118,122,126,130,135,140,145,147,152,155,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":141,"doc_module":4,"doc_module_name":25,"category_name":142,"show_sort_weight":143,"slug":144},7,"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":98,"slug":146},"research-report",{"id":148,"doc_module":4,"doc_module_name":25,"category_name":149,"show_sort_weight":150,"slug":151},9,"Religion & Spirituality",20,"religion-spirituality",{"id":150,"doc_module":4,"doc_module_name":25,"category_name":153,"show_sort_weight":150,"slug":154},"World Cup","world-cup",{"id":156,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":156,"slug":158},10,"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":131,"slug":162},19,"General","general"]